ChuCY, ChoiJ, Eaby-SandyB, et al.Osimertinib: A novel dermatologic adverse event profile in patients with lung cancer. Oncologist. 2018; 23(8):891–899; doi: 10.1634/theoncologist.2017-0582
2.
Miremont-SalaméG, ThéophileH, HaramburuF, et al.Causality assessment in pharmacovigilance: The French method and its successive updates. Therapie. 2016; 71(2):179–186; doi: 10.1016/j.therap.2016.02.010
3.
Alchaikh HassanR, SolimanA, DasanuCA. Oral lichenoid drug eruption due to osimertinib for lung cancer. J Oncol Pharm Pract. 2024; 30(7):1278–1281; doi: 10.1177/10781552241268693
4.
CheraghlouS, LevyLL. Fixed drug eruptions, bullous drug eruptions, and lichenoid drug eruptions. Clin Dermatol. 2020; 38(6):679–692; doi: 10.1016/j.clindermatol.2020.06.010
